ESC 22 Late-breaker Discussion: The ADVOR Trial

Published: 29 Aug 2022

  • Views:

    Views Icon 1281
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

SC Congress 22 — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sat down with the principal investigator of the ADVOR trial (NCT03505788), Prof Wilfried Mullens (Hospital Oost-Limburg (ZOL), BE) to talk about the trial design and practical consideration in light of the new data. 
ADVOR, a multi-center, randomized, double-blind clinical trial assessed the diuretic effects of acetazolamide (Diamox®) in patients with decompensated heart failure with at least one clinical sign of volume overload. 
Patients (519) in this trial were randomised into two groups. Patients in the first group received standard care with high-dose loop diuretics and placebo. The second group of patients received high-dose loop diuretics with acetazolamide.
Primary outcome measure was treatment success, secondary outcome measures included mortality, hospital readmission, length of hospital stay at 3 months and EuroQoL five dimensions questionnaire (EQ-5D). 

Recorded on-site ESC Congress 22, Barcelona.

Editor: Mirjam Boros, Jordan Rance

Videography: Mike Knight, Oliver Miles